###### Strengths and limitations of this study

-   A large human papillomavirusHPV vaccination trial cohort with standardised clinical and laboratory procedures.

-   The repeated self-reported study questionnaires were comprehensive and less subject to recall bias.

-   Use of the overall cervical atypia endpoint increases study power but may have diluted the effects.

Introduction {#s1}
============

Sexually transmitted human papillomavirus (HPV) infections cause both cytological and histological cervical abnormalities.[@R1] Clinical manifestations of persistent infection with oncogenic HPV types and squamous intraepithelial lesions (SILs) of the cervix, also known as cervical intraepithelial neoplasia (CIN), are the precursors of invasive cervical cancer (ICC).[@R3] In addition to HPV, other risk factors which may play a role in the pathogenesis of ICC are smoking,[@R6] *Chlamydia trachomatis*,[@R7] lifetime number of sexual partners (LNSPs),[@R8] age at first sexual intercourse (FSI),[@R9] parity[@R10] and the use of oral contraceptives (OCs).[@R11]

Both early age at FSI and early age at the start of OC use are associated with an increased risk of SIL and CIN.[@R9] Furthermore, a short lag between menarche and FSI is a risk factor of SIL/CIN.[@R9] This is probably due to exposure of immature cervical cells to infection with HPV, as persistent infections with oncogenic HPV types are established more readily in an immature cervix.[@R13] However, whether or not early start of OC use has an independent role here is unknown. The interplay of the time interval between age at the start of OC use or FSI and menarche in cervical carcinogenesis has not been studied.

In a large cohort study, we have investigated whether the risk of cervical atypia is associated with a short interval between menarche and the age at the start of OC use or FSI.

Materials and methods {#s2}
=====================

Study sample {#s2-1}
------------

The study population consists of women enrolled in the control arm of a double-blinded, multi-national randomised control PATRICIA trial whose primary aim was to evaluate the vaccine efficacy of the HPV 16/18 vaccine against CIN2+.[@R16] Full description of the trial, details of recruitment and final results on its endpoints have been reported earlier.[@R18] PATRICIA enrolled only 16--17-year-old women in Finland (2409 received at least one dose of HPV 16/18 vaccine) and 2399 women (received at least one dose of hepatitis A virus (HAV) vaccine). The criteria of having no more than six LNSPs was not applied in Finland, so all women interested and willing to participate in the study were included.[@R18] Written informed consent was obtained from all the participants.

The present study began after the end of the clinical PATRICIA trial. All 4808 women who were approximately 22 years old when exiting the trial were sent a questionnaire on living conditions, lifestyle habits and sexual health. All the women (913) who had received the HAV vaccine, answered the questionnaires both at enrolment and at the end of the follow-up, and had negative cytology at baseline and before menarche were eligible ([table 1](#T1){ref-type="table"}). Cytology outcomes were detected at the follow-up visits.

###### 

Characteristics of 22-year-old women (n=913) who attended eight biannual follow-up visits and a subgroup of these women (n=197) who developed cervical atypia during 4 years of follow-up

  Characteristics          Attendees   Women with atypia         
  ------------------------ ----------- ------------------- ----- ------
  Age                                                            
   22                      422         46.2                94    47.7
   23                      489         53.6                103   52.3
   24                      2           0.2                 0     0
   Missing                 0           0                   0     0
  Age at menarche                                                
   ≤11                     194         21.3                52    26.4
   12--14                  659         72.2                136   69.0
   ≥15                     52          5.7                 6     3.10
   Missing                 8           0.8                 3     1.5
  Age at FSI                                                     
   12--16                  602         65.9                129   65.5
   17--22                  273         29.9                60    30.5
   Missing                 38          4.2                 8     4.0
  LNSPs                                                          
   0                       3           0.3                 1     0.5
   1                       131         14.3                29    14.7
   2--4                    283         31.0                57    28.9
   5--9                    236         25.9                50    25.4
   ≥10                     230         25.2                55    28.0
   Missing                 30          3.3                 5     2.5
  OC use                                                         
   Non-user                62          6.8                 15    7.6
   User                    842         92.2                179   90.9
   Missing                 9           1.0                 3     1.5
  Age at start of OC use                                         
   12--16                  504         55.2                104   52.8
   17--22                  371         40.6                85    43.1
   Missing                 38          4.2                 8     4.1
  Condom use                                                     
   Non-user                414         45.4                97    49.2
   User                    406         44.5                83    42.1
   Don\'t know             76          8.3                 16    8.1
   Missing                 17          1.8                 1     0.5
  Smoking                                                        
   Never                   525         57.5                108   54.8
   Past                    93          10.2                16    8.1
   Present                 291         31.9                73    37.1
   Missing                 4           0.4                 0     0
  HPV 16                                                         
   Negative                711         77.9                145   73.6
   Positive                201         22.0                52    26.4
  HPV 18                                                         
   Negative                792         86.8                165   83.8
   Positive                120         13.1                32    16.2
  *Chlamydia*                                                    
   Negative                811         88.8                175   88.8
   Positive                102         11.2                22    11.2

FSI, first sexual intercourse; HPV, human papillomavirus; LNSPs, lifetime number of sexual partners; OC, oral contraceptive.

Data collection {#s2-2}
---------------

In addition to collecting information on living conditions and lifehabits, the questionnaires collected information about history of OC use, use of other contraceptives, smoking, menarche and sexual habits. The end of study questionnaire was more complete regarding the initiation of sexual habits, and was therefore used in the analysis. The age at the start of OC use, menarche and age at FSI were the independent variables in this study. Intervals of \<3 years, or more than or equal to 3 years were calculated between menarche and the age at the start of OC use, as well as between menarche and FSI. Data on smoking ('never smokers', 'past smokers' and 'present smokers'), LNSPs ('none', '1', '2--4', '5--9' and 'more than 10'), condom use ('non-user', 'user' and 'do not know') and sexually transmitted infections (HPV 16/18 and *C. trachomatis*) were used as covariables, as they are important factors in cervical carcinogenesis. These covariables were used in both the univariate and multivariable models to evaluate if the short intervals between menarche and FSI or age at the start of OC use are truly associated with or modify the risk of cervical atypia.

Laboratory analysis and endpoints {#s2-3}
---------------------------------

In the PATRICIA trial, biannual cervical cytological and DNA samples were obtained in conjunction with pelvic examination. PCR analyses for *C. trachomatis* and HPV DNA were performed as described.[@R18]

At the follow-up visits, the first cytological findings of atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL) were registered as index incident cases for the statistical analysis. Colposcopy-directed biopsy samples were also obtained during the trial. The first histopathological findings of CIN grades 1, 2 and 3 were also listed as the index cases for statistical analysis. SIL and CIN cases were combined together to form a new variable, cervical atypia.

Cervical atypia findings were registered by the interval between menarche and FSI or the start of OC use to form four mutually exclusive different individual outcome variables; (1) cervical atypia with shorter than 3 years lag between menarche and FSI, (2) cervical atypia with equal or longer than 3 years lag between menarche and FSI, (3) cervical atypia with shorter than 3 years lag between menarche and OC use and (4) cervical atypia with equal or longer than 3 years lag between menarche and OC use.

Patient and public involvement {#s2-4}
------------------------------

Patient (adolescent study subjects) and public (parental) involvement in the planning and design of the study was noted as their attitudes and willingness to participate in a HPV vaccination trial in a questionnaire sent to households (parents and their adolescent daughter) in one of the major study site communities.[@R19] No patients with cervical cytological atypia were involved in setting the research questions, the outcome measures or in developing the plans for recruitment, design or implementation of the study.

There are no plans to directly disseminate the results of the research to study participants; however, the results have and will be disseminated to a wider audience, including members of the public, patients, health professionals and experts through written communication, events and conferences, networks and social media.

Statistical analysis {#s2-5}
--------------------

The outcome variables were analysed in the univariate and multivariable logistic regression models along with the independent variables and above listed covariates. The risks are reported as the ORs with 95% CI. The statistical analysis was performed using Stata V.14.0 (Stata Corp LP, Statistical Software: Release 14).

Results {#s3}
=======

Baseline characteristics of our study cohort attending biannual follow-up visits for 4 years are materially homogeneous with little variation ([table 1](#T1){ref-type="table"}).

Age at menarche was between 12 and 14 years for 659 (72.2%) participants. Age at the FSI and age at the start of OC use were between 12 and 16 years for 602 (65.9%) and 504 (55.2%) participants, respectively. No cervical atypia cases were found before the menarche, age at the FSI or the age at the start of OC use. One cervical atypia case occurring concomitantly with the start of OC use was removed from the analyses.

By the end of the follow-up period, out of 913 women, 156 (17.1%) had ASCUS, 189 (20.7%) had LSIL, 5 (0.6%) had HSIL, 40 (4.4%) had CIN1, 22 (2.41%) had CIN2 and 8 (0.9%) had CIN3. 197 (21.6%) of 913 women were identified with cervical atypia ([table 1](#T1){ref-type="table"}). Almost one-third of the women with cervical atypia (55 (28.0%) of 197) had more than 10 LNSPs. Half of the women with or without cervical atypia, 49.2% and 45.4% respectively, did not regularly use condoms. Most of the women (179 (90.9%) of 197) with cervical atypia had used OCs. Age at the start of OC use for the majority of these women (104 (52.8%) of 197) was between 12 and 16 years ([table 1](#T1){ref-type="table"}). During the 4 year follow-up, 201 (22%) of all women were tested positive for HPV 16 and 120 (13.1%) were tested positive for HPV 18 ([table 1](#T1){ref-type="table"}). One-third of women with either HPV 16 or HPV 18, or both were diagnosed with cervical atypia during the follow-up. The number of women who tested positive for *C. trachomatis* was 102 (11.2%), and the number of *C. trachomatis* positive women with cervical atypia was 22 (11.2%) ([table 1](#T1){ref-type="table"}).

We categorised the risk factors of cervical atypia according to the interval between menarche and age at the start of OC use, or between menarche and age at FSI using a stratification of \<3 years and ≥3 years ([table 2](#T2){ref-type="table"}).

###### 

Distribution of cervical atypia risk factors by interval between menarche and age at the start of OC use or age at the FSI in young adult women followed up for 4 years

  Category                      Interval between menarche and age at the start of OC use   Interval between menarche and the FSI                
  ----------------------------- ---------------------------------------------------------- --------------------------------------- ------------ ------------
  *Chlamydia trachomatis*       39 (20.3)                                                  59 (8.7)                                54 (18.0)    44 (7.8)
  HPV 16                        55 (28.7)                                                  142 (21.1)                              97 (32.2)    100 (17.8)
  HPV 18                        35 (18.2)                                                  83 (12.3)                               47 (15.6)    71 (12.5)
  HPV 16/18                     69 (35.9)                                                  190 (28.2)                              115 (38.2)   144 (25.4)
  Smoking                                                                                                                                       
   Never                        84 (43.8)                                                  405 (60.4)                              134 (44.8)   356 (63.0)
   Past smoker                  22 (11.4)                                                  69 (10.2)                               37 (12.4)    54 (9.6)
   Present smoker               86 (44.8)                                                  197 (29.4)                              128 (42.8)   155 (27.4)
  Age at menarche               13.4 (1.2)                                                 12.2 (1.1)                              13.1 (1.3)   12.1 (1.1)
  Age at FSI                    14.7 (1.2)                                                 16.3 (1.9)                              14.6 (1.2)   16.7 (1.9)
  Age at start of OC use        14.9 (1.2)                                                 16.9 (1.7)                              15.3 (1.3)   17.1 (1.7)
  Lifetime number of partners                                                                                                                   
   0                            0                                                          1 (0.2)                                 0            1 (0.2)
   1                            11 (5.7)                                                   119 (17.6)                              14 (4.6)     116 (20.5)
   2--4                         46 (24.0)                                                  230 (34.1)                              73 (24.2)    204 (36.0)
   5--9                         69 (36.0)                                                  163 (24.2)                              98 (32.5)    134 (23.7)
   \>10                         66 (34.4)                                                  162 (24.0)                              117 (38.7)   111 (19.6)

FSI, first sexual intercourse; HPV, human papillomavirus; OC, oral contraceptive.

The mean ages at menarche, at FSI and at the start of OC use were similar in the corresponding categories ([table 2](#T2){ref-type="table"}). Women in the \<3 years interval categories were more often HPV 16 positive than women in the ≥3 years interval categories ([table 2](#T2){ref-type="table"}). The percentages of women with multiple (\>5) LNSPs were also higher in the short interval categories ([table 2](#T2){ref-type="table"}).

In the univariate analysis, the risk of cervical atypia associated with its known risk factors was evaluated separately in the short and long interval categories ([table 3](#T3){ref-type="table"}).

###### 

Relative risk (ORs with 95% CI) of cervical atypia (cytological SIL and/or CIN grade 1 or worse, CIN1+) associated with different covariables in analyses stratified by the interval between menarche and age at FSI (category 1), or between menarche and the age at start of OC (category 2) use in young adult women followed up for 4 years

  Variable     Frequency and relative risk of cytological atypia: SIL or CIN1 in the different categories by interval from menarche                                                                                         
  ------------ ---------------------------------------------------------------------------------------------------------------------- ------------------ --------- ------------------ -------- ------------------ --------- ------------------
  HPV 16/18                                                                                                                                                                                                                 
   Positive    21/115                                                                                                                 1.0 (0.6 to 2.0)   45/144    1.8 (1.1 to 2.7)   13/69    1.4 (0.6 to 3.0)   53/190    1.4 (1.0 to 2.1)
   Negative    33/186                                                                                                                 1                  87/422    1                  18/123   1                  102/484   1
  Chlamydia                                                                                                                                                                                                                 
   Positive    14/54                                                                                                                  1.8 (1.0 to 3.6)   8/44      0.7 (0.3 to 1.6)   10/39    2.2 (1.0 to 5.1)   12/59     0.8 (0.4 to 1.6)
   Negative    40/248                                                                                                                 1                  124/522   1                  21/153   1                  143/616   1
  Smoking                                                                                                                                                                                                                   
   Yes         34/165                                                                                                                 1.5 (0.8 to 2.7)   52/209    1.1 (0.8 to 1.7)   22/108   2.1 (1.0 to 5.0)   64/266    1.1 (0.8 to 1.6)
   No          20/134                                                                                                                 1                  80/356    1                  9/84     1                  91/405    1
  Condom use                                                                                                                                                                                                                
   Yes         22/146                                                                                                                 0.7 (0.4 to 1.2)   59/256    0.9 (0.6 to 1.3)   15/102   0.6 (0.3 to 1.3)   66/300    0.9 (0.6 to 1.3)
   No          29/139                                                                                                                 1                  61/251    1                  16/80    1                  74/309    1
  LNSPs                                                                                                                                                                                                                     
   High        39/215                                                                                                                 1.1 (0.6 to 2.0)   64/245    1.3 (0.9 to 2.0)   24/135   1.5 (0.6 to 3.8)   79/325    1.2 (0.8 to 1.7)
   Low         15/87                                                                                                                  1                  68/321    1                  7/57     1                  76/350    1

\*Five or more.

CIN, cervical intraepithelial neoplasia; FSI, first sexual intercourse; LNSPs, lifetime number of sexual partners; OC, oral contraceptive; SIL, squamous intraepithelial lesion.

Cervical atypia risk estimates associated with HPV 16/18 were increased (OR 1.8, 95% CI 1.1 to 2.7 and OR 1.4, 95% CI 1.0 to 2.1) in the longer (≥3 years) interval categories. On the contrary, the cervical atypia risk associated with *C. trachomatis* was increased (OR 1.8, 95% CI 1.0 to 3.6 and OR 2.2, 95% CI 1.0 to 5.1) in the short (\<3 years) interval categories. Condom use was not associated with a significantly decreased risk of cervical atypia in any of the interval categories ([table 3](#T3){ref-type="table"}).

In univariate analyses, the risk of cervical atypia associated with the short interval between menarche and age at the start of OC use appeared to be somewhat decreased (OR 0.7, 95% CI 0.4 to 1.3) when the interval between menarche and age at the FSI was short ([table 4](#T4){ref-type="table"}).

###### 

Relative risk (ORs with 95% CI) of cervical atypia (cytological SIL and/or CIN grade 1 or worse, CIN1+) stratified by the interval between menarche and age at FSI or between menarche and the age at start of OC use in young adult women followed up for 4 years

  Frequency and relative risk of cytological atypia: SIL or CIN1 in the different categories by interval from menarche                                                                                 
  ---------------------------------------------------------------------------------------------------------------------- -------- ------------------ -------------------- --------- ------------------ --------------------
  Lag between FSI and menarche                                                                                                                                                                         
   \<3 years.                                                                                                            53/301   NA                                      23/110    0.9 (0.5 to 1.4)   0.9 (0.8 to 1.0)
   ≥3 years                                                                                                              NA       NA                                      132/565   1                  \*Interval (cont.)
  Lag between start of OCs and menarche                                                                                                                                                                
   \<3 years.                                                                                                            30/191   0.7 (0.4 to 1.3)   0.9 (0.9 to 1.0)     NA        NA                 
   ≥3 years                                                                                                              23/110   1                  \*Interval (cont.)   155/675   NA                 

CIN, cervical intraepithelial neoplasia; FSI, first sexual intercourse; OC, oral contraceptive; SIL, squamous intraepithelial lesion.

The risk estimate, however, approached unity (OR 0.9) when the interval was estimated as a continuous variable. There was no risk of atypia associated with the long-term interval between menarche and the start of OC use ([table 4](#T4){ref-type="table"}).

In multivariable analyses, stepwise exclusion of one variable at a time from the multivariable model was performed to check the interdependency of the interval between menarche, age at the start of OC use and age at FSI in this context. Exclusion of any of the abovementioned variables did not affect significance of the estimates (data not shown).

Discussion {#s4}
==========

We found that cervical atypia was not associated with early start of sexual activity after menarche. The risk of cervical atypia associated with *C. trachomatis* was increased shortly after start of sexual activity following menarche, whereas the risk of cervical atypia was associated with HPV 16/18 infections more than 3 years after the start of sexual activity following menarche.

Our large HPV-vaccination-trial-derived population of young adult women, with uniform ethnicity (97% Caucasian Finnish women), and the standardised clinical and laboratory procedures are noteworthy strengths of the study. In young Finnish women, HIV infection has been and is extremely rare ([www.thl.fi](www.thl.fi)). Furthermore, over the entire follow-up period the trial participants received regular sexual health counselling which probably helped in retaining the participants and reduced possible confounding and bias in our study. To the best of our knowledge, the association between interval between menarche and the age at the start of OC use with cervical atypia has now been assessed for the first time.

Some limitations of our study are as follows. The use of the overall cervical atypia endpoint, which was necessary to retain the statistical power of the study strata. The study questionnaires used were self-reported at the ages of 18 and 22 years, the latter of which is subject to recall bias. The endpoint questionnaire (at age 22) was, however, in line with the enrolment questionnaire (at age 18), for example, for menarche. Moreover, questionnaire-based information regarding sexual behaviour is supposed to have adequate validity and reliability.[@R20] It gave the most comprehensive information about sexual risk-taking characteristics of the study subjects over time. This was important when assessing the longitudinal effects of OC use on prospective development of cervical atypia following the exposures. Free contraceptives were distributed to the participants during the trial period, which might have increased the proportions of OC and condom users in our study.

The absence of HPV 16/18 associated risk of cervical atypia in women with short lag between menarche and the start of sexual activity appears to defy the assumption that the immature cervical transformation zone is especially prone to persistent HPV infection.[@R15] Our observation is in line with Collins *et al*, who reported that the increased interval between menarche and the age at the FSI increases the risk of HPV infection.[@R22] Overall cervical atypia, the most common clinical manifestation of genital HPV infection, needs some time to develop.

On the other hand, our findings seem to contradict a study by Ruiz *et al* who first reported that short interval between menarche and age at the FSI is a predictor of cervical cytological abnormalities and CIN.[@R9] While our homogeneous study population had ampler power to detect a threefold increased risk (see [online supplementary appendix](#SP1){ref-type="supplementary-material"}), their study population was heterogeneous and had only baseline sexual risk-taking behaviour questionnaire data, which could not elaborate (possible changes in) the risk-taking behaviour during the follow-up. Furthermore, we found a lack of association between short interval of menarche and two different measures of the start of sexual activity (age at FSI and age at the start of OC use). However, these different observations on the interval between menarche and start of sexual activity, and the risk of cervical atypia,[@R9] may also reflect limited sample sizes.
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Our group has earlier reported that when *C. trachomatis* infection precedes or cooccurs with HPV infection the risk of high-grade cervical neoplasia associated with the joint infection is very high.[@R23] Our results on the increased risk of *C. trachomatis* infection with cervical atypia especially in women with a short lag between menarche and the start of sexual activity emphasise the need to identify, treat and follow-up adolescent females with *C. trachomatis*.

In conclusion, while our study does not support the hypothesis that a short interval between menarche and age at the start of sexual activity always increases the risk of cervical atypia, early age of acquiring *C. trachomatis* infections may set the stage for cervical carcinogenesis and should be identified and treated.
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